Free Newsletter
Top Story
Report: Roche transferring Israeli diabetes operations to Europe
Less than two years after paying $200 million for diabetes pump developer Medingo, Roche's diagnostic division ($RHHBY) is shutting down the company and transferring its operations from Israel to Europe. Article
Latest News
Also Noted
> The FDA has approved subcutaneous delivery for Millennium/Takeda's blood cancer drug Velcade for all previously approved indications. Release
> Arrogene NanoTechnology raised $500,000 toward development of new diagnostic and therapeutic drugs based on a new family of nano-biopolymers. Release
> Drug developer Zogenix and research and development organization Battelle will work on expanding treatment options for Zogenix's DosePro technology, which uses compressed gas, rather than a needle injection, to deliver a liquid drug through the skin. Release
Read more >>Press Releases
- BWH Researchers Develop New Drug Release Mechanism Utilizing 3D Superhydrophobic Materials
- Discovery of new vaccine approach for treatment of cancer
- Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
- Celator Pharmaceuticals Receives EMA Orphan Drug Status for CPX-351 in Acute Myeloid Leukemia
- New startup out of University of Illinois, Vanquish Oncology, to Develop Personalized Therapeutics for Cancer Markets
- U.S. Food And Drug Administration Approves Pfizer’s INLYTA® (axitinib) For Patients With Previously Treated Advanced Renal
Popular Comment Threads
Report
This could be the year of nanotech-enabled medicines
Nanotech-enabled medicines are coming of age.
That's the big message I came away with after a recent telephone chat with Kevin Bitterman, a life sciences investor with Polaris Venture Partners in Waltham, MA.
Report
